The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy.
The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy.
复制标题
DOI：
10.1158/1055-9965.epi-08-0377
复制
发表时间：
2009-01
期刊：
影响因子：
--
通讯作者：
Scarpinato KD
中科院分区：
文献类型：
--
作者：
Norris AM;Gentry M;Peehl DM;D'Agostino R Jr;Scarpinato KD
The inability to predict clinical outcome of prostate cancer is a major impediment to effective treatment decisions and patient counseling. New markers of recurrence are needed to improve the accuracy of risk assessment and treatment of prostate cancer. Our previous studies identified a mismatch repair protein, PMS2, to be elevated in prostate cancer; here we investigate the prognostic potential of this marker. We hypothesized that the elevation of PMS2 would correlate with disease outcome. Retrospective quantitative immunohistochemistry was performed to measure PMS2 in high grade cancers of 166 men treated by radical prostatectomy with a biochemical recurrence rate of 56%. Associations between PMS2 levels, pathological variables and biochemical recurrence over time were determined. The mean level of PMS2 protein was consistently higher in both cancer-associated benign epithelium and cancer cells of patients who recurred, compared to non-recurrent patients. PMS2 was an independent predictor of time-to-recurrence in Cox multivariate analyses and significantly stratified patients based on outcome. PMS2 was able to improve the sensitivity of total percent Gleason 4/5 as a risk factor for recurrence in this cohort. PMS2 protein levels were shown to be a predictor of time-to-recurrence after surgery. This study is the first to document that the elevation of a mismatch repair protein negatively correlates with prognosis and has implications in patient diagnosis and molecular profiling.
